Background. Although international studies of young gastric cancer patients have mainly reported favorable survival outcomes compared with older patients, US-based experiences have shown a wider spectrum of outcomes. We examined the impact of young age (under 45 years) on the presentation and survival outcomes of gastric adenocarcinoma. Methods. A total of 33,236 patients with gastric adenocarcinoma were identified within the 1988-2006 Surveillance, Epidemiology, and End Results (SEER) registry. Multivariate regression analysis of relative survival was performed to adjust for covariate effects using generalized linear models. Results. Young patients were more likely than older patients to have advanced nodal and distant metastatic disease at presentation (P \ 0.001 for both). Unadjusted relative survival analysis demonstrated younger patients to have favorable stage-stratified survival when compared with middle-aged and older patients. These findings persisted after adjusting for covariates. After stratifying for receipt of cancer-directed surgery, younger age was associated with more favorable stage-stratified relative survival. Conclusions. This is the largest US population-based study of age-related gastric cancer outcomes. Although young patients with gastric cancer present with more advanced disease, their adjusted stage-stratified relative survival is more favorable than that of older patients. This study supports a stage-dependent treatment approach in younger populations.
Gastric adenocarcinoma remains the second leading cause of cancer-related deaths worldwide. Although this cancer's overall incidence continues to decline in the USA, the expected numbers of new cases are projected to increase to 1 million in 2010, in part because of an increasing-and aging-world population. 1 In 2005 there were 21,860 newly diagnosed cases of-and 11,550 deaths from-gastric adenocarcinoma in the USA. [2] [3] [4] Nearly half of these patients were over 70 years of age, and nearly 10% were under 45 years (young group). [5] [6] [7] [8] [9] [10] [11] Although young persons are less commonly affected by gastric cancer, there has been a common perception that they have worse prognosis than older patients. Young patients became the focus of several studies from Europe and Asia, which have mainly reported favorable survival outcomes of young patients surgically treated for gastric cancer. 12, 13 However, US-based studies have demonstrated a wide prognostic spectrum among young patients with gastric cancer. 10, 11, 14 It has been reported that gastric adenocarcinoma exhibits more aggressive behavior in patients under 40 years old than in patients over 40 years old, with median survival durations of 11-16 months versus 33 months, respectively. 10, 15 Others have reported that younger age was not associated with survival outcome [hazard ratio (HR) 1.13; 95% confidence interval (CI) 0.83-1.5; P [ 0.10] when factors such as serosal or nodal involvement were considered. 11 Thus far, studies evaluating survival outcomes of young patients with gastric cancer in the USA remain mixed and are mostly limited to experiences from single-center and regional studies.
We hypothesized that previously observed poor outcomes among young patients with gastric cancer are due to advanced stage at presentation and that stage-stratified, covariate-adjusted survival outcomes in younger patients with gastric cancer are comparable to those of other age groups. To test our hypothesis and to better understand the clinical presentation, treatment, and prognosis of gastric adenocarcinoma in the USA, we examined these factors in young gastric adenocarcinoma patients using a large US population-based tumor registry.
METHODS

Data Source
Data from the Surveillance, End Results, and Epidemiology (SEER) program of the National Cancer Institute (released in 2009) were utilized for this study. 16 SEER, a population-based cancer registry, collects cancer incidence and survival data from 17 regional population-based registries covering approximately 26% of the US population. Since 1988, SEER registries have collected data on patient demographics, primary tumor sites, tumor morphology, and American Joint Committee on Cancer (AJCC) stage at diagnosis, first course of treatment (if surgery and/or radiation), and vital status upon follow-up. When the first course of treatment includes both radiation and surgical therapy, the sequence of administration is reported. SEER also reports the status of regional lymph nodes, including total number recovered and total number involved with metastatic disease. We did not evaluate variables for which SEER does not collect data, such as comorbidities, resection margin status, short-term operative outcomes, and systemic chemotherapy.
Study Population
Using the SEER registry, we identified those patients diagnosed between January 1991 and December 2006 with adenocarcinoma of the stomach. We included patients for whom the diagnosis of gastric adenocarcinoma was their first and only cancer diagnosis. We excluded patients with SEER-defined gastroesophageal junction tumors.
Patients were categorized by age: younger than 45 years, aged 45-70 years, and older than 70 years. Our rationale for this grouping was twofold: firstly, to remain consistent with prior studies that have generally defined younger gastric cancer patients as those aged below 40 or 45 years while also including a middle-aged group as a referent; secondly, comparisons of young patients with those over age 70 years may be complicated by coexisting comorbidities associated with older age and thus may not allow for meaningful comparisons.
Patient-, tumor-, and treatment-related factors were compared among age groups. Tumor-related factors included the location of the primary tumor in the stomach, histologic grade, and AJCC 6th edition stage. For tumor location within the stomach, we categorized the patients as having tumors of the proximal third (cardia C16.0 and fundus C16.1), mid third (body C16.2 and lesser curvature C16.5), distal third (antrum C16.3 and pylorus C16.4), greater curvature (C16.6), or overlapping lesions of the stomach (C16.8). Tumors were histologically categorized into low grade (well and moderately differentiated) versus high grade (poorly differentiated, undifferentiated, and anaplastic tumors). All cases were recoded according to the AJCC Cancer Staging Manual, 6th edition criteria from the SEER extent of disease codes. 17 For treatment-related factors, we included receipt of gastric cancer-directed surgery and of adjuvant radiotherapy.
Statistical Analysis
For our univariate analyses, patient demographics, tumor factors, and treatment types were compared by age groups using the chi-square test for proportions and Student's t test for means. Overall survival (OS) was assessed using the Kaplan-Meier method and the log-rank test for univariate comparisons. Relative survival analysis was calculated as the ratio of the observed survival to the expected survival for the US general population individually matched for age, sex, and the year of which the age was coded. Relative survival analysis accounts for potential errors in cause-of-death information within SEER and competing causes of death and provides an approximation of cancer-specific survival. To assess the impact of age (as a factor) on stagestratified relative survival adjusted for covariate influences, we utilized a relative survival regression model using generalized linear models with the Poisson assumption for the observed number of deaths. 19 To determine our final logistic regression models, we used forward selection and included both variables that were significant in the univariate analyses and those with clinical relevance. We considered P \ 0.05 to be statistically significant. All statistical analyses in this report were performed using STATA10 MP software (StataCorp, College Station, TX).
RESULTS
Patient Demographics
A total of 33,236 patients with gastric adenocarcinoma were identified from the SEER tumor registry from 1988 through 2006. Of these, 2,757 (8.3%) were younger than 45 years, 16,603 (49.9%) were aged between 45 and 70 years, and 13,876 (41.7%) were older than 70 years (Table 1) . Median patient age at diagnosis was 68 years [interquartile range (IQR) 57-76 years]. There was a male preponderance in all three age groups. However, among the youngest and oldest groups, women accounted for a greater proportion than in the middle-aged group. Although the most common racial/ethnic group in each category was White, there were higher proportions of non-Whites in younger cohorts than in older ones.
Tumor-Related Features
Proximal gastric tumors (cardia and fundus) represented the most frequent primary tumor location in each age group of gastric cancer patients. Young patients were more likely to have tumors with higher histologic grades than were the other age groups (for all, P \ 0.001). They were also more likely to present with higher proportions of AJCC T3, T4, N3, and M1 disease stages than were those in both older age groups (for all, P \ 0.001). The mean number of lymph nodes examined after cancer-directed surgery was higher among the youngest patients (14.5) than the middleaged (13.8, P = 0.0.036) or the oldest group (11.9, P \ 0.001). Moreover, the proportion of patients who had 15 or more lymph nodes examined after gastric surgery was higher among the young patients (39.4%) than the middle-aged (35.6%, P \ 0.001) or oldest patients (28.4%, P \ 0.001).
Types of Treatment
Overall, there were significant age-related differences in rates of gastric cancer-directed surgery, likely reflecting both age-and stage-related effects. However, among those who did undergo cancer-directed surgery, increasing age was significantly associated with decreasing use of adjuvant radiation therapy (for all comparisons, P \ 0.0001).
Relative Survival Outcomes
On univariate survival analysis, relative survival outcomes were significantly more favorable among the young cohort when compared with either the middle-aged or oldest cohort. These observations remained true for all stage strata (Figs. 1, 2, 3 4) . The observed findings on unadjusted relative survival persisted after adjustment (for sex, race, marital status, primary tumor location, tumor grade, use of radiation, undergoing cancer-directed surgery, and number of lymph nodes examined) in the stagestratified relative survival regression analysis, demonstrating that the association between younger age and better overall survival outcome was true ( Table 2) . We next evaluated only those patients who underwent cancerdirected surgery and noted that the favorable effect of young age on improved survival outcomes persisted (Table 2) .
DISCUSSION
Our population-based analysis demonstrated that young patients with gastric adenocarcinoma, when compared with older aged cohorts, are more likely to present with advanced or metastatic disease. However, after stratifying for stage at presentation, the young patients have survival outcomes that are more favorable than their older counterparts. To our knowledge, the present study is the largest contemporary population-based analysis in the USA examining the presentation, treatment, and survival outcomes for young patients with gastric adenocarcinoma and one of the first to demonstrate improved survival among young patients.
Our findings regarding the nature of the cancer at presentation are consistent with prior reports of gastric adenocarcinoma in young patients. Young patients (less than 40 years) in a Southern California cancer registry were more likely to have tumors with advanced grade and signet ring cell histology than were older patients (more than 40 years). Furthermore, young patients have been observed to have higher rates of advanced nodal and distant metastatic disease (either at time of diagnosis or upon surgical exploration). [6] [7] [8] 14 However, there have been conflicting reports regarding survival outcomes of gastric cancer among young patients. 10, 15 A number of studies have reported that young patients have generally worse survival outcomes, suggesting more aggressive disease biology, while others have observed no age-related effects. 10, 20, 21 Most studies have been generally limited by small numbers of patients, inclusion of historical patients, lack of comparison with similar control groups, and limited ability to account for disease-specific survival. In our analysis we showed that young age was actually associated with improved survival after stratification by stage at presentation and adjustment for covariate effects. As relative survival analysis has been shown to be a good approximation of disease-free survival, our findings suggest that stage at presentation is the most important predictor of outcome and that the improved survival among the young patients likely results from greater ability to tolerate cancer-directed therapies.
Our finding of more advanced gastric cancer in the young cohort, consistent with other studies, has been attributed to several factors. First, the incidence of gastric cancer is lower among younger cohorts. Given the overlap of its presenting features with other common benign conditions (e.g., gastroesophageal reflux disease), gastric cancer in young persons may intuitively not be considered at the time of presentation. Second, gastric cancer has a declining incidence in the USA and generally more advanced features than in Asia, where it is more common. Therefore, there has been little incentive to establish surveillance endoscopy programs to identify patients at an earlier stage. As our understanding of the molecular [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] biology of gastric cancer continues to evolve, as in diffuse gastric cancer, a subset of persons at higher risk may be identified. Early identification of this subset of persons may decrease the proportion of disease diagnosed at locally advanced or metastatic stages, especially in younger persons.
Our study has limitations inherent to the dataset and changes to the AJCC staging system. There were some cases for which incomplete information did not allow for complete AJCC stage assignment, such as in cases where no cancer-directed surgery was performed. However, given the large number of patients within the study cohort, in order to reduce the potential effect of bias due to lower rates of cancer-directed surgery in the oldest cohorts, the stage-stratified analyses were performed using data from those patients with complete staging information. We also considered the changes to the AJCC 7th edition and applied them to our primary analysis, but this did not affect our findings that younger patients presented with more advanced disease but with more favorable outcomes than their stage-matched older cohorts (data not shown). Our study did exclude patients with Siewart type III gastroesophageal junction tumors, which are currently coded as esophageal cancers within SEER, thus eliminating the confounding of its treatment and prognosis. 22 Secondly, the timeframe of the current study overlaps with the natural evolution of the AJCC staging system for gastric cancer. It is possible that the current analysis cannot account for the unmeasured variations in practice for gastric cancer care in previous years. Thirdly, the SEER registry does not report data on comorbidities, which may affect subsequent treatment and survival. This analysis is also subject to age-related selection bias. We therefore examined covariate-adjusted relative survival to measure the excess mortality in the gastric cancer patients relative to the general population. This method adjusts for differences in observed survival that may be attributed to competing causes of death, thereby avoiding the pitfalls of potential errors in causeof-death information (e.g., miscoding) on cancer-specific survival outcomes, a particularly relevant issue when considering age-related outcomes. 23 Our study has implications for future investigation of gastric cancer in young patients. The present study represents one of the largest population-based analyses in North America examining the presentation survival outcomes of young patients with gastric adenocarcinoma. Our results support a stage-dependent rather than age-dependent approach in the management of gastric cancer in young patients. Secondly, our study offers relevant information on the advanced patterns of gastric cancer in younger persons. These results may help to maximize the utility of diagnostic laparoscopy, peritoneal cytology, and consideration for neoadjuvant therapy protocols, thus avoiding the pitfalls of nontherapeutic laparotomy.
In conclusion, this large US population-based study showed that young patients with gastric cancer presented with more advanced disease; however, their stage-stratified relative survival was more favorable than that of older patients. This study validates previous international experiences and supports a stage-dependent treatment approach in younger populations. Model adjusted for sex, race, marital status, primary tumor location, tumor grade, use of radiation, undergoing cancer-directed surgery, and number of lymph nodes examined. Cases with unknown surgery or radiation status were excluded AJCC American Joint Committee on Cancer, CI confidence interval
